Repurposing of cyclophilin A inhibitors as broad-spectrum antiviral agents

Cyclophilin A (CypA) is linked to diverse human diseases including viral infections. With the worldwide emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2), drug repurposing has been highlighted as a strategy with the potential to speed up antiviral development. Because CypA acts as a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jinhe, Lee, Myoung Kyu, Jang, Yejin, Cho, Won-Jea, Kim, Meehyein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Keynote (Green)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9123807/
https://www.ncbi.nlm.nih.gov/pubmed/35609743
http://dx.doi.org/10.1016/j.drudis.2022.05.016
Descripción
Sumario:Cyclophilin A (CypA) is linked to diverse human diseases including viral infections. With the worldwide emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2), drug repurposing has been highlighted as a strategy with the potential to speed up antiviral development. Because CypA acts as a proviral component in hepatitis C virus, coronavirus and HIV, its inhibitors have been suggested as potential treatments for these infections. Here, we review the structure of cyclosporin A and sanglifehrin A analogs as well as synthetic micromolecules inhibiting CypA; and we discuss their broad-spectrum antiviral efficacy in the context of the virus lifecycle.

Ejemplares similares